The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Survivin: A molecular biomarker in cancer
Open accessAbstract
Survivin, a member of the inhibitor of apoptosis (IAP) protein family that inhibits caspases and blocks cell death, is highly expressed in most cancers and is associated with a poor clinical outcome. Survivin has consistently been identified by molecular profiling analysis to be associated with high tumour grade cancers, different disease survival and recurrence. Polymorphisms in the survivin gene are emerging as powerful tools to study the biology of the disease and have the potential to be used in disease prognosis and diagnosis. The survivin gene polymorphisms have also been reported to influence tumour aggressiveness as well as survival of cancer patients. The differential expression of survivin in cancer cells compared to normal tissues and its role as a nodal protein in a number of cellular pathways make it a high target for different therapeutics. This review discusses the complex circuitry of survivin in human cancers and gene variants of survivin, and highlights novel therapy that targets this important protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,244
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Survivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53
Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., & Murphy, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106643200 · Cited by 794
dbSNP—database for single nucleotide polymorphisms and other classes of minor genetic variation
Sherry, S. T., Ward, M., & Sirotkin, K. (1999) · Genome Research · doi:10.1101/gr.9.8.677 · Cited by 789
Cited by
Yu, T., Li, Y., Gu, X., & Li, Q. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.532457 · Cited by 94
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
An OX-Tra’Ordinary tale: the role of OX40 and OX40L in atopic dermatitis
Sadrolashrafi, K., Guo, L., Kikuchi, R., Hao, A., Yamamoto, R. K., Tolson, H. C., Bilimoria, S. N., Yee, D. K., & Armstrong, A. W. (2024) · Cells · doi:10.3390/cells13070587 · Cited by 28
Geisen, M. E., Tessmann, J. W., Kelson, C. O., He, D., Wang, C., Faisal, A. S. M., Beswick, E. J., Baca, Y., Rock, S., Kolesar, J. M., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101283
“Resistant cells showed accelerated growth in vitro and in vivo , with increased Cyclin D1 and survivin, proteins known to drive apoptosis resistance, cell-cycle checkpoint bypass, and therapy resistance [16,17].”
Metadata
- Authors
- Mittal, R., Jaiswal, P., & Goel, A.
- Venue
- Indian Journal of Medical Research
- Publisher
- Scientific Scholar
- Published
- 2015
- Volume
- 141
- Issue
- 4
- Pages
- 389
- ISSN
- 0971-5916 (ISSN-L)
- OpenAlex
- W1853943513
- Cited by
- 352
- References
- 64
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survivin: A molecular biomarker in cancer. https://app.cochat.ai/papers/10.4103/0971-5916.159250
- The paper
- Mittal, R., Jaiswal, P., & Goel, A. (2015). Survivin: A molecular biomarker in cancer. Indian Journal of Medical Research. https://doi.org/10.4103/0971-5916.159250
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
